HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Treatment of metastatic malignant melanoma localized to an extremity].

AbstractBACKGROUND:
At the Norwegian Radium Hospital, most patients who were treated for metastases (localized to an extremity) from malignant melanoma in the period 1977-99 underwent intra-arterial chemotherapy combined with radiotherapy. We have evaluated the effects of this treatment, which has now been replaced by isolated limb perfusion (with melphalan and tumor necrosis factor).
MATERIAL AND METHODS:
Medical records were reviewed for patients with metastatic malignant melanoma (localized to an extremity) who had been treated at the Norwegian Radium Hospital with intra-arterial chemotherapy (5-[3,3 dimethyl-1-triazeno]-imidazole-4-carboxamide [DTIC]) in the period 1977-99.
RESULTS:
36 patients had received such treatment; in 30 of these the induction treatment was combined with radiation of the tumour area.. 24 patients were in complete remission after treatment (12 of these had all the metastases surgically removed before treatment). Nine patients had a partial remission while three patients had progressive disease. Median observation time was 49 months. 15 of 31 patients had an observation time of more than five years, and seven of these patients were alive after ten years. Three patients with metastasis localized to the lower extremity died of other causes. In one case the intra-arterial catheterisation caused serious aortic damage.
INTERPRETATION:
It is possible to achieve long-term remission in patients with metastatic malignant melanoma localized to an extremity after intra-arterial chemotherapy combined with radiotherapy.
AuthorsKari Dolven Jacobsen, Johan Tausjø, Bjarne Hager, Stein Gundersen
JournalTidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke (Tidsskr Nor Laegeforen) Vol. 130 Issue 1 Pg. 21-4 (Jan 14 2010) ISSN: 0807-7096 [Electronic] Norway
Vernacular TitleBehandling av melanommetastaser på ekstremitetene.
PMID20094118 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Dacarbazine
Topics
  • Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, therapeutic use)
  • Dacarbazine (administration & dosage, adverse effects, therapeutic use)
  • Female
  • Humans
  • Infusions, Intra-Arterial
  • Lower Extremity (pathology)
  • Male
  • Melanoma (drug therapy, radiotherapy, secondary)
  • Middle Aged
  • Prognosis
  • Radiotherapy, Adjuvant
  • Registries
  • Remission Induction
  • Retrospective Studies
  • Skin Neoplasms (drug therapy, radiotherapy, secondary)
  • Survival Rate
  • Treatment Outcome
  • Upper Extremity (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: